A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

ClinicalTrials.gov ID: NCT04913285

Public ClinicalTrials.gov record NCT04913285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Study identification

NCT ID: NCT04913285
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pierre Fabre Medicament; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Interventions

KIN-2787 Drug
KIN-2787 and binimetinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 3, 2021
Primary completion: Nov 29, 2028
Completion: Mar 29, 2029
Last update posted: Sep 1, 2026

2021 – 2029

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
The Angeles Clinic	Los Angeles	California	90025-6602	Recruiting
UCLA	Los Angeles	California	90095	Recruiting
University of California San Diego, Moores Cancer Center	San Diego	California	92093	Recruiting
University of California San Francisco	San Francisco	California	94143-2205	Recruiting
Sarah Cannon Research Institute Denver	Denver	Colorado	80218-1238	Recruiting
Mayo Clinic - Florida	Jacksonville	Florida	32224	Recruiting
Sarah Cannon Research Institute - Florida Cancer Specialists	Orlando	Florida	32827	Recruiting
Mayo Clinic - Rochester	Rochester	Minnesota	55905	Recruiting
Atlantic Health	Morristown	New Jersey	07960	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Recruiting
NYU Langone	New York	New York	10016	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
Sarah Cannon Research Institute-Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
MD Anderson	Houston	Texas	77030	Not yet recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04913285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04913285 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →